• RBC Capital Markets started coverage of Cytokinetics (NASDAQ:CYTK) with an outperform rating, citing valuation.
• “With shares down 50% since their January peak, we think the $3.6B opportunity driven by aficamten’s convenience, safety and efficacy in HCM is not being fully valued,” the investment bank wrote

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.